Rivia, a Swiss bio-analytics startup, has secured EUR 3 million (USD 3.2 million) in a seed funding round led by Speedinvest, alongside Amino Collective and Nina Capital.
The funds will be used to hire new engineering and client services team members. Additionally, the company plans to use part of the funds to advance its product development and strengthen its market position.
Based in Switzerland, Rivia specializes in providing a platform for clinical trial data integration and management. Its platform provides real-time insights and improves trial management efficiency by centralizing diverse data sources into a single, cohesive view.
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.